78 results about "In vitro system" patented technology

The present invention provides an in vitro system for compartmentalization of molecular or cellular libraries and provides methods for selection and isolation of desired molecules or cells from the libraries. The library includes a plurality of distinct molecules or cells encapsulated within a water-in-oil-in-water emulsion. The emulsion includes a continuous external aqueous phase and a discontinuous dispersion of water-in-oil droplets. The internal aqueous phase of a plurality of such droplets comprises a specific molecule or cell that is within the plurality of distinct molecules or cells of the library.

A method for studying scaffold-based tissue engineering approaches in combination with the use of progenitor or stem cells to generate new lung tissue in an in vitro system. The engineered tissue system of this invention is used to monitor lung and immune system exposure of pathogen and/or toxins. The method involves growing engineered lung/immune tissue from progenitor cells in a bioreactor and then exposing the engineered lung/immune tissue to a pathogen and/or toxin. Once exposed, response of the engineered tissue is monitored to determine the effects of exposure to the immune component of the tissue and to lung component of the tissue. This invention also involves development of mixed engineered tissues including a first fully functional engineered tissue such as lung tissue and a second fully functional engineered tissued such as immune tissue from a single animal donor. The mixed systems can include more than two engineered tissues.

A microfluidic device for culturing cells, termed a microscale cell culture analog (μCCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro/in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.

The present invention provides methods and, accordingly, in vitro systems for generating stable and soluble oligomers of amyloid proteins, under physiological pH and temperature; and hence, a system for identifying and validating drugs that have the potential to prevent formation of soluble oligomers of amyloid proteins, to disaggregate soluble oligomers of amyloid proteins already formed and possibly disaggregate downstream larger insoluble aggregates of amyloid proteins.

An in vitro system in which immune cells of a non-immunized pig are used for assessing immunoactivity of a substance.

The invention provides a preparation method of a yeast cell extracting solution, the yeast cell extracting solution and a method for synthesizing protein in an in vitro system by virtue of the yeast cell extracting solution, as well as a kit containing the yeast cell extracting solution. The kit, which is more convenient than a conventional method, is applicable to protein synthesis in the in vitro system; transformation, culture and crushing can be prevented; a great amount of using time and cost can be saved; various types of proteins can be expressed, and influence of protein toxicity can be prevented; and a plurality of protein complexes can be expressed, without the use of a high temperature at 37 DEG C. In addition, as a raw material adopted by the invention, yeast cell is simple to cultivate, convenient to operate, rapid to propagate and relatively low in cost; a prepared yeast extract has a capacity of modifying translated protein, the yeast extract is suitable for large-scale preparation and has an advantage of industrial production; and the yeast cell extract, which is prepared into freeze-dried powder by virtue of a vacuum freeze-drying method and is preserved at low temperature or high temperature, is convenient to transport.

A activator for prekallikrein includes isolated, purified, or substantially purified heat shock protein 90, a phosphate ion, and mixtures thereof. The prekallikrein activator is part of an in vitro system for activating prekallikrein in the absence of FXIIa. The system includes the activator, high-molecular weight kininogen, and zinc ions. A method for activating prekallikrein to produce kallikrein in the absence of FXIIa includes mixing prekallikrein with the activator and a composition comprising high molecular weight kininogen and zinc ions. A method for evaluating the activity of a test drug for the production of kallikrein comprises activating prekallikrein and determining the kallikrein produced. The activity (promoting or inhibiting ability) of the tested drug against the production of kallikrein in the absence of FXIIa can be easily measured. The test drug may be an analgesic, anti-allergy, anti-inflammatory drug.

Methods for detecting nonactivated basophils in a whole blood sample obtained from a normal healthy subject, methods for determining a subject's susceptibility to an allergic reaction to an allergen, where the subject has no known allergy to the allergen, methods for measuring a response to challenge with a potential allergen in a whole blood sample obtained from a subject with known allergic reactivity to allergens other than the potential allergen; and an in vitro system for reliable detection or quantification of a specific white blood cell population in a whole blood sample are described.

The invention provides the components of in vivo and in vitro systems and methods which use them to study the effects of altered expression of a gene activity, such as the human akt, bcl-2, eIF4E or PTEN activities, on the descendants of stem cells that have been engineered to give rise to hematopoietic tumorigenic or tumor cells, such as lymphomas, with a high frequency. The present invention provides vectors, cells and mammals, and methods which in part depend on such products, useful for understanding tumorigenesis and its treatments, and in particular, for identifying and studying inhibitors and activators associated with tumor cell growth and growth inhibition, cell death through apoptotic pathways, and changes in apoptotic pathway components that affect drug sensitivity and resistance in tumorigenic cells. Methods for identifying molecular targets for drug screening, identifying interacting gene activities, for identifying therapeutic treatments and for identifying candidates for new therapeutic treatments are provided.

The present invention provides in vitro systems for use in identifying modulators of neural differentiation. Also provided are modulators identified by these systems. The present invention further provides methods for identifying a modulator of neural differentiation, a modulator of a Wnt signalling pathway, a modulator of Wnt-dependent neural differentiation, a modulator of a BMP signalling pathway, a modulator of BMP-dependent neural differentiation, a modulator of a Hh signalling pathway, and a modulator of Hh-dependent neural differentiation. Also provided are modulators identified by these methods.

The invention discloses a rapid screening method for comprehensively evaluating the in-vitro inhibitory effect of nine human liver CYP450 metabolic enzymes by utilizing 14 probe substrates and 16 probe reaction. The invention mainly relates to a method for monitoring metabolic activity variation of 9 human liver CYP450 enzymes and rapidly and comprehensively evaluating an inhibitory effect of a tested compound on the metabolic enzyme by adopting an in-vitro mixed probe incubation method and LC/MS/MS. According to the method, the exclusiveness and diversity of the probe substrate, interaction of the probe substrates, influence of different inoculation conditions (by charging organic solvent, buffer solution and BSA) in a warm inoculation system and the enzyme kinetics characteristics of 16 probe reactions under the selected inoculation condition are comprehensively considered, a brand new in-vitro system is established by integrating high-sensitive and high-selective LC-MS/MS technology, so that the inhibitory effect of the tested compounds on the nine human liver main metabolic enzymes can be more accurately and comprehensively predicted in the high-throughput screening of the novel drug development, and the predictability on the interaction of the later metabolism can be improved.

Compositions, methods and kits for in vitro systems for synthesis of biomolecules such as polypeptides, are provided herein. Cell extracts that provide enhanced yields of soluble proteins using in vitro protein synthesis methods are provided. The invention also includes methods for producing high yields of proteins by the addition of a feeding solution that includes amino acids and an energy source to an ongoing in vitro synthesis system. The invention also includes methods of using a high-yield in vitro synthesis system to produce large quantities of proteins with incorporated labeled amino acids for analysis by methods such as by NMR. The invention further includes vectors for enhanced production of proteins from nucleic acid templates using in vitro synthesis systems.

The present invention relates to recombinant hepatitis C virus (HCV)-derived nucleic acids and to stable rapidly growing cell clones derived from human hepatoma Huh-7 cell line and supporting high titer replication of said recombinant HCV nucleic acids. The subgenomic HCV replicons and cell clones of the instant invention represent the in vitro system of choice for studies of HCV propagation, anti-viral drug screening, and vaccine development.

Methods of preparing and using neural cells derived from human induced pluripotent stem cell (hiPSCs), particularly hiPSCs derived from subjects with schizophrenia are provided. The hiPSC-derived neural cells can be used to screen test compounds and to identify schizophrenia marker functions. The hiPSC-derived neural cells can be used to diagnose and/or assess the severity of schizophrenia in a subject. Further, may the hiPSC-derived neural cells from a subject be used as an in vitro system to identify the most effective candidate among existing drugs for that specific subject (i.e. personalized medicine).

Methods for identifying modulators of fatty acid transport and/or uptake, comprising contacting, under conditions favorable for fatty acid uptake, a putative modulator, e.g., an inhibitor with a system comprising genetic material encoding a fatty acid transport mediator (“TTM”), particularly FAA1, FAA2, FAA3, FAA4, FAT1, fadL, fadD, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, or fatty acid transport mediator proteins (“TTMps”), e.g., Faa1p, Faa2p, Faa3p, Faa4p, Fat1p, FadL, fatty acyl CoA synthetase, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, and determining the effect of the putative modulator. The test system may be a cell such as Saccharomyces cerevisiae, E. coli, H. sapiens, etc. or an in vitro system.

Solanum viarum is an alkaloid producing plant of the family Solanaceae with varied therapeutic uses. In order to grow the plant in large areas; one needs to have an efficient system of vegetative multiplication, which ensures its genetic uniformity, and true to the type nature. In nature largely seeds propagate plant, which could be result of cross-pollination which may result in genetic drift. The present invention provides an efficient micropropagation system, with high level of multiplication at relatively low cost of production. The multiplication ratio was as high as 1:6 and almost 95% the plants were viable and successfully cultivated in field. The present invention provides an ideal way of mass cultivation of the selected elite plant material.

The invention provides a therapeutic apparatus provided with submucous implanted electrodes and capable of automatically sensing alimentary tract successive pacemaking. The therapeutic apparatus comprises an implanted system controller, multiple sensors used for detecting activities of an alimentary tract, multiple implanted electrodes and an in-vitro system controller, wherein the signal inlet end of the implanted system controller can be connected with the sensors used for detecting the activities of the alimentary tract; and the signal output end of the implanted system controller is connected with the implanted electrodes. The therapeutic apparatus can be used for receiving a group or multiple groups of signals input by the multiple sensors; the group or multiple groups of signals are analyzed by virtue of the implanted system controller so as to recognize a specific state of the alimentary tract; and the implanted system controller outputs multiple groups of stimulation signals output by the one or multiple implanted electrodes by virtue of one or multiple signal generators, and the stimulation signals are used for stimulating muscles around each implanted electrode to finish contractile activity. The therapeutic apparatus can be implanted into a patient and stayed in the patient for a long time, and can be used for generating one or more groups of successive simulation signals according to the motion state of the alimentary tract of the patient and stimulating the alimentary tract to recover to a normal physiological status.

Described herein are compositions and methods for identifying cellular factors involved in protein agglomeration. One such factor is a nucleic acid component. Another factor is a cellular binding factor. The nucleic acid components, and methods of using them, to interact with agglomeration proteins are also disclosed herein. The nucleic acid compositions herein comprise one or more DNA or RNA molecules having affinity for at least one agglomeration protein. The nucleic acid component is a naturally or non-naturally occurring molecule with twenty or more ribonucleotide bases. For RNA, at least one nucleotide sequence portion of this RNA molecule has affinity to at least one consensus sequence present in the agglomeration RNA-binding protein. Methods disclosed herein are directed towards detecting the presence of one or more agglomeration proteins in a sample matrix using the amplibody compositions described herein. Also described herein is an in vitro system (“TRIPARTITE”), which utilizes a NA and a non-NA chaperone to analyze the amyloid disease progression and test drugs potentially useful in combating such diseases. Also described are in vivo, transgenic animal models for analyzing amyloid diseases and agents potentially useful in combating those diseases.

This description applies to pharmaceutical compositions comprising a mixture comprising one or more hERG1 channel blockers in combination with one or more compounds for anticancer therapy for use in the treatment of chemoresistant or potentially chemoresistant leukaemias and in vitro systems for the screening of substances suitable for use in the treatment of chemoresistant or potentially chemoresistant leukaemias.